Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bluebird Bio (NQ: BLUE )

0.3778 -0.0022 (-0.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Bluebird bio's Neurological Disorder Gene Therapy Wins CHMP Backing for Approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc’s... 
Via Benzinga
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Enveric Biosciences (NASDAQ:ENVB)... 
Via Benzinga
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
From bluebird bio, Inc.
Via Business Wire
NASDAQ:BLUE Long Term Investor Alert: Investigation of Potential Wrongdoing at Bluebird Bio Inc
San Diego, CA -- (SBWIRE) -- 05/12/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of bluebird bio Inc. 
Via SBWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces May Investor Events
From bluebird bio, Inc.
Via Business Wire
What Investors Need to Know About This $419,500 CAR-T Cancer Treatment
Abecma is on the market. 
Via The Motley Fool
Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock?
The competition is starting to heat up, but bluebird is far from finished. 
Via The Motley Fool
bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations
From bluebird bio, Inc.
Via Business Wire
Is bluebird bio a Bad News Buy?
The biotech has had a rough couple of years. 
Via The Motley Fool
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)
From The Law Offices of Frank R. Cruz
Via Business Wire
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
TUESDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.